Improving identification of familial hypercholesterolaemia in primary care: Derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT)

Atherosclerosis

Volumn 238, Issue 2, 2015, Pages 336-343

  Weng, Stephen F ^a   Kai, Joe ^a   Andrew Neil, H ^b   Humphries, Steve E ^c   Qureshi, Nadeem ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b WOLFSON COLLEGE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Epidemiology; Familial; Hypercholesterolaemia; Lipids; Primary care

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE FINDING; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; COHORT ANALYSIS; DIABETES MELLITUS; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERCHOLESTEROLEMIA CASE ASCERTAINMENT TOOL; FAMILY HISTORY; FEMALE; HEART INFARCTION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; SENSITIVITY ANALYSIS; VALIDATION STUDY; VERY ELDERLY; AREA UNDER THE CURVE; BLOOD; DECISION SUPPORT SYSTEM; FACTUAL DATABASE; GENETIC PREDISPOSITION; GENETICS; HEREDITY; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE; PRIMARY HEALTH CARE; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, LDL; DATABASES, FACTUAL; DECISION SUPPORT TECHNIQUES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEREDITY; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TRIGLYCERIDES; YOUNG ADULT;

EID: 84920160399     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.034     Document Type: Article

References (34)

1. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 2013, 34(45):3478-3490.
2. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991, 303(6807):893-896. Simon-Broome Register Group.
3. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999, 142(1):105-112. Simon-Broome Register Group.
4. Neil A., Cooper J., Betteridge J., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J. 2008, 29(21):2625-2633.
5. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011, 32(14):1769-1818.
6. Minhas R., Humphries S.E., Qureshi N., Neil H.A.W. Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart Br. Card. Soc. 2009, 95(7):584-587.
7. Neil H.A., Hammond T., Huxley R., Matthews D.R., Humphries S.E. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000, 321(7254):148.
8. Dhiman P., Kai J., Horsfall L., Walters K., Qureshi N. Availability and quality of coronary heart disease family history in primary care medical records: implications for cardiovascular risk assessment. PLoS One 2014, 9(1):e81998.
9. Hoffman M.A. The genome-enabled electronic medical record. J.Biomed. Informatics 2007, 40(1):44-46.
10. Bates T.R., Burnett J.R., Bockxmeer FMv, Hamilton S., Arnolda L., Watts G.F. Detection of familial hypercholesterolaemia: a major treatment gap in preventative cardiology. Heart Lung Circulation 2008, 17(5):411-413.
11. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001, 286(11):1317-1324.
12. Qureshi N., Humphries S.E., Seed M., Rowlands P., Minhas R. Identification and management of familial hypercholesterolaemia: what does it mean to primary care?. Br. J. General Pract. 2009, 59(567):773-776.
13. Herrett E., Thomas S.L., Schoonen W.M., Smeeth L., Hall A.J. Validation and validity of diagnoses in the general practice research database: a systematic review. Br. J. Clin. Pharmacol. 2010, 69(1):4-14.
14. National Institute for Health and Care Excellence Identification and Management of Familial Hypercholesterolaemia 2008, National Institute of Health and Care Excellence, London.
15. Marks D., Thorogood M., Neil H.A., Humphries S.E. Areview on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003, 168(1):1-14.
16. Kolovou G.D., Kostakou P.M., Anagnostopoulou K.K. Familial hypercholesterolemia and triglyceride metabolism. Int. J. Cardiol. 2011, 147(3):349-358.
17. Miller M., Stone N.J., Ballantyne C., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123(20):2292-2333.
18. Williams R.R., Hunt S.C., Schumacher M.C., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 1993, 72(2):171-176.
19. Stone N.J. Stopping statins. Circulation 2004, 110(16):2280-2282.
20. National Institute for Health and Care Excellence Draft for consultation: Lipid Modification - Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease 2014, National Institute of Health and Care Excellence, London.
21. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326(7404):1423.
22. National Institute for Health and Care Excellence Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease 2008, National Institute for Health and Care Excellence, London, UK.
23. Newson R. Confidence intervals for rank statistics: Somers' D and extensions. Stata J. 2006, 6(3):309-334.
24. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice European Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2012, 33(13):1635-1701.
25. PRIMIS. Software Tools - CHART [accessed 10.08.14]. http://www.nottingham.ac.uk/primis/tools/chart/chart.aspx.
26. Technical Steering Committee General Practice Trends in the UK 2013, Health and Social Care Information Centre, London, UK.
27. Marang-van de Mheen P.J., ten Asbroek A.H.A., Bonneux L., Bonsel G.J., Klazinga N.S. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands. Eur. Heart J. 2002, 23(24):1922-1930.
28. Marks D., Wonderling D., Thorogood M., Lambert H., Humphries S.E., Neil H.A.W. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002, 324(7349):1303.
29. Qureshi N., Armstrong S., Dhiman P., et al. Effect of adding systematic family history enquiry to cardiovascular disease risk assessment in primary care: a matched-pair, cluster randomized trial. Ann. Intern Med. 2012, 156(4):253-262.
30. Qureshi N., Carroll J.C., Wilson B., et al. The current state of cancer family history collection tools in primary care: a systematic review. Genet. Med. Official J. Am. Coll. Med. Genet. 2009, 11(7):495-506.
31. Gray J., Jaiyeola A., Whiting M., Modell M., Wierzbicki A.S. Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart Br. Card. Soc. 2008, 94(6):754-758.
32. Talmud P.J., Shah S., Whittall R., et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013, 381(9874):1293-1301.
33. Futema M., Whittall R.A., Kiley A., et al. Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic. Atherosclerosis 2013, 229(1):161-168.
34. Hippisley-Cox J., Coupland C., Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ 2013, 346:f2573.